Systematic Review of Effectiveness of Oral Sirolimus After Bare-Metal Stenting of Coronary Arteries for Prevention of In-Stent Restenosis

      Neointimal hyperplasia after percutaneous coronary intervention is a major determinant of in-stent restenosis (ISR). Drug-eluting stents (DES) mitigate neointimal hyperplasia and thereby lead to a lower rate of ISR compared with bare-metal stents (BMS). Recent studies have demonstrated that short-term use of oral sirolimus after BMS leads to a significant reduction in ISR. We therefore sought to do a systematic review of studies to determine the angiographic and clinical benefits of early short-term use of oral sirolimus after BMS of native coronary arteries. We conducted PubMed, Embase, Cochrane database review, and Web of Science search of studies comparing oral sirolimus after BMS to BMS alone or DES. Outcomes analyzed were ISR and target lesion revascularization (TLR) as well as major adverse cardiovascular events. A total of 488 patients from 4 studies were included in the review (2006 to 2010). Three studies, comparing BMS alone versus BMS plus oral sirolimus, demonstrated significant reduction in ISR in the oral sirolimus group. Two of these studies also demonstrated significant reduction in TLR at 6-12 month follow-up. The fourth study comparing BMS plus oral sirolimus versus DES showed a lower but nonsignificant reduction in TLR in addition to significant cost saving in the group treated with oral sirolimus. In conclusion, our systematic review demonstrates that early short-term systemic use of sirolimus after BMS resulted in a significant reduction in ISR and TLR. In addition, ISR rates were comparable to DES with the added benefit of cost saving.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Martin K.A.
        • Rzucidlo E.M.
        • Merenick B.L.
        • Fingar D.C.
        • Brown D.J.
        • Wagner R.J.
        • Powell R.J.
        The mTOR/p70 S6K1 pathway regulates vascular smooth muscle cell differentiation.
        Am J Physiol Cell Physiol. 2004; 286: C507-C517
        • Fattori R.
        • Piva T.
        Drug-eluting stents in vascular intervention.
        Lancet. 2003; 361: 247-249
        • Stefanini G.G.
        • Holmes Jr., D.R.
        Drug-eluting coronary-artery stents.
        N Engl J Med. 2013; 368: 254-265
        • Brito Jr., F.S.
        • Rosa W.C.
        • Arruda J.A.
        • Tedesco H.
        • Pestana J.O.
        • Lima V.C.
        Efficacy and safety of oral sirolimus to inhibit in-stent intimal hyperplasia.
        Catheter Cardiovasc Interv. 2005; 64: 413-418
        • Laskey W.K.
        • Yancy C.W.
        • Maisel W.H.
        Thrombosis in coronary drug-eluting stents: report from the meeting of the Circulatory System Medical Devices Advisory Panel of the Food and Drug Administration Center for Devices and Radiologic Health, December 7-8, 2006.
        Circulation. 2007; 115: 2352-2357
        • Kaneda H.
        • Koizumi T.
        • Ako J.
        • Terashima M.
        • Morino Y.
        • Honda Y.
        • Yock P.G.
        • Leon M.B.
        • Moses J.W.
        • Fitzgerald P.J.
        Impact of intravascular ultrasound lesion characteristics on neointimal hyperplasia following sirolimus-eluting stent implantation.
        Am J Cardiol. 2005; 96: 1237-1241
        • Farb A.
        • John M.
        • Acampado E.
        • Kolodgie F.D.
        • Prescott M.F.
        • Virmani R.
        Oral everolimus inhibits in-stent neointimal growth.
        Circulation. 2002; 106: 2379-2384
        • Poon M.
        • Marx S.O.
        • Gallo R.
        • Badimon J.J.
        • Taubman M.B.
        • Marks A.R.
        Rapamycin inhibits vascular smooth muscle cell migration.
        J Clin Invest. 1996; 98: 2277-2283
        • Chaves A.J.
        • Sousa A.G.
        • Mattos L.A.
        • Abizaid A.
        • Feres F.
        • Staico R.
        • Centemero M.
        • Tanajura L.F.
        • Abizaid A.C.
        • Rodrigues A.
        • Paes A.
        • Mintz G.S.
        • Sousa J.E.
        Pilot study with an intensified oral sirolimus regimen for the prevention of in-stent restenosis in de novo lesions: a serial intravascular ultrasound study.
        Catheter Cardiovasc Interv. 2005; 66: 535-540
        • Guarda E.
        • Marchant E.
        • Fajuri A.
        • Martinez A.
        • Moran S.
        • Mendez M.
        • Uriarte P.
        • Valenzuela E.
        • Lazen R.
        Oral rapamycin to prevent human coronary stent restenosis: a pilot study.
        Am Heart J. 2004; 148: e9
        • Rodriguez A.E.
        • Alemparte M.R.
        • Vigo C.F.
        • Pereira C.F.
        • Llaurado C.
        • Russo M.
        • Virmani R.
        • Ambrose J.A.
        Pilot study of oral rapamycin to prevent restenosis in patients undergoing coronary stent therapy: Argentina Single-Center Study (ORAR Trial).
        J Invasive Cardiol. 2003; 15: 581-584
        • Brara P.S.
        • Moussavian M.
        • Grise M.A.
        • Reilly J.P.
        • Fernandez M.
        • Schatz R.A.
        • Teirstein P.S.
        Pilot trial of oral rapamycin for recalcitrant restenosis.
        Circulation. 2003; 107: 1722-1724
        • Rodriguez A.E.
        • Rodriguez Alemparte M.
        • Vigo C.F.
        • Fernandez Pereira C.
        • Llaurado C.
        • Vetcher D.
        • Pocovi A.
        • Ambrose J.
        Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial).
        Heart. 2005; 91: 1433-1437
        • Waksman R.
        • Ajani A.E.
        • Pichard A.D.
        • Torguson R.
        • Pinnow E.
        • Canos D.
        • Satler L.F.
        • Kent K.M.
        • Kuchulakanti P.
        • Pappas C.
        • Gambone L.
        • Weissman N.
        • Abbott M.C.
        • Lindsay J.
        Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: the Oral Rapamune to Inhibit Restenosis (ORBIT) study.
        J Am Coll Cardiol. 2004; 44: 1386-1392
        • Hausleiter J.
        • Kastrati A.
        • Mehilli J.
        • Vogeser M.
        • Zohlnhofer D.
        • Schuhlen H.
        • Goos C.
        • Pache J.
        • Dotzer F.
        • Pogatsa-Murray G.
        • Dirschinger J.
        • Heemann U.
        • Schomig A.
        Randomized, double-blind, placebo-controlled trial of oral sirolimus for restenosis prevention in patients with in-stent restenosis: the Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) trial.
        Circulation. 2004; 110: 790-795
        • Rodriguez A.E.
        • Fernandez Pereira C.
        • Rodriguez Alemparte M.
        Oral rapamycin in the treatment of diffuse proliferative in-stent restenosis in a patient with small reference vessel.
        J Invasive Cardiol. 2003; 15: 515-518
        • Rodriguez A.E.
        • Maree A.
        • Tarragona S.
        • Fernandez-Pereira C.
        • Santaera O.
        • Rodriguez Granillo A.M.
        • Rodriguez-Granillo G.A.
        • Russo-Felssen M.
        • Kukreja N.
        • Antoniucci D.
        • Palacios I.F.
        • Serruys P.W.
        Percutaneous coronary intervention with oral sirolimus and bare metal stents has comparable safety and efficacy to treatment with drug eluting stents, but with significant cost saving: long-term follow-up results from the randomised, controlled ORAR III (Oral Rapamycin in ARgentina) study.
        EuroIntervention. 2009; 5: 255-264
        • Rodriguez A.E.
        • Rodriguez-Granillo A.M.
        • Antoniucci D.
        • Mieres J.
        • Fernandez-Pereira C.
        • Rodriguez-Granillo G.A.
        • Santaera O.
        • Rubilar B.
        • Palacios I.F.
        • Serruys P.W.
        Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
        Catheter Cardiovasc Interv. 2012; 80: 385-394
        • Cernigliaro C.
        • Sansa M.
        • Vitrella G.
        • Verde A.
        • Bongo A.S.
        • Giuliani L.
        • Novelli E.
        Preventing restenosis after implantation of bare stents with oral rapamycin: a randomized angiographic and intravascular ultrasound study with a 5-year clinical follow-up.
        Cardiology. 2010; 115: 77-86
        • Rodriguez A.E.
        • Granada J.F.
        • Rodriguez-Alemparte M.
        • Vigo C.F.
        • Delgado J.
        • Fernandez-Pereira C.
        • Pocovi A.
        • Rodriguez-Granillo A.M.
        • Schulz D.
        • Raizner A.E.
        • Palacios I.
        • O'Neill W.
        • Kaluza G.L.
        • Stone G.
        Oral rapamycin after coronary bare-metal stent implantation to prevent restenosis: the Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study.
        J Am Coll Cardiol. 2006; 47: 1522-1529
        • Stojkovic S.
        • Ostojic M.
        • Nedeljkovic M.
        • Stankovic G.
        • Beleslin B.
        • Vukcevic V.
        • Orlic D.
        • Arandjelovic A.
        • Kostic J.
        • Dikic M.
        • Tomasevic M.
        Systemic rapamycin without loading dose for restenosis prevention after coronary bare metal stent implantation.
        Catheter Cardiovasc Interv. 2010; 75: 317-325
        • Ryan T.J.
        • Faxon D.P.
        • Gunnar R.M.
        • Kennedy J.W.
        • King 3rd, S.B.
        • Loop F.D.
        • Peterson K.L.
        • Reeves T.J.
        • Williams D.O.
        • Winters Jr., W.L.
        Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty).
        Circulation. 1988; 78: 486-502
        • Babapulle M.N.
        • Joseph L.
        • Belisle P.
        • Brophy J.M.
        • Eisenberg M.J.
        A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.
        Lancet. 2004; 364: 583-591
        • Stone G.W.
        • Moses J.W.
        • Ellis S.G.
        • Schofer J.
        • Dawkins K.D.
        • Morice M.C.
        • Colombo A.
        • Schampaert E.
        • Grube E.
        • Kirtane A.J.
        • Cutlip D.E.
        • Fahy M.
        • Pocock S.J.
        • Mehran R.
        • Leon M.B.
        Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
        N Engl J Med. 2007; 356: 998-1008
        • Keogh A.
        • Richardson M.
        • Ruygrok P.
        • Spratt P.
        • Galbraith A.
        • O'Driscoll G.
        • Macdonald P.
        • Esmore D.
        • Muller D.
        • Faddy S.
        Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial.
        Circulation. 2004; 110: 2694-2700
        • Eisen H.J.
        • Tuzcu E.M.
        • Dorent R.
        • Kobashigawa J.
        • Mancini D.
        • Valantine-von Kaeppler H.A.
        • Starling R.C.
        • Sorensen K.
        • Hummel M.
        • Lind J.M.
        • Abeywickrama K.H.
        • Bernhardt P.
        Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients.
        N Engl J Med. 2003; 349: 847-858
        • Dasari T.W.
        • Hennebry T.A.
        • Hanna E.B.
        • Saucedo J.F.
        Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature.
        Catheter Cardiovasc Interv. 2011; 77: 962-969
        • Raber L.
        • Magro M.
        • Stefanini G.G.
        • Kalesan B.
        • van Domburg R.T.
        • Onuma Y.
        • Wenaweser P.
        • Daemen J.
        • Meier B.
        • Juni P.
        • Serruys P.W.
        • Windecker S.
        Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study.
        Circulation. 2012; 125: 1110-1121
        • Barone-Rochette G.
        • Machecourt J.
        • Vanzetto G.
        • Foote A.
        • Quesada J.L.
        • Castelli C.
        • Danchin N.
        • Combescure C.
        The favorable price evolution between bare metal stents and drug eluting stents increases the cost effectiveness of drug eluting stents.
        Int J Cardiol. 2013; (S0167–5273(12)01683-X)